Últimas noticias sobre Novo Nordisk (NYSE:NVO) Bolsa

Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

AADI

APTO

CADL

CARA

HUMA

MESO

MOBX

MTEM

NVNI

OCEA

PRFX

QUBT

ZCAR

FedEx sube un 8,7% con resultados sólidos y una nueva estrategia. Descubre otras acciones destacadas en premercado hoy.

Las acciones de FedEx (FDX) suben alrededor de un 9%; 20 acciones que se mueven en premercado

Biotech

Large Cap

News

Health Care

Movers

General

Novo Nordisk revela datos sobre Amycretina, un nuevo medicamento para pérdida de peso, que mostró una baja del 13,1% en peso en 12 semanas.

Novo Nordisk presenta resultados de su nuevo fármaco para pérdida de peso, Amycretina

Novo Nordisk AS

Novo Resources Corp Warrants (27/08/2023)

NOVO INTEGRATED SCIENCES by Novo Integrated Sciences, Inc.

Novo Integrated Sciences Inc

Tidal Trust II Defiance Daily Target 2X Long NVO ETF

An endorsement of a weight-loss drug by world's richest man Elon Musk could prove beneficial in the battle between two health care companies seeing revenue growth and soaring stock prices as interest in <a href="https://www.benzinga.com/topic/weight-loss-drug">weight-loss drugs grows.</a>
What Happened: A post from Musk on Christmas shared his latest take on weight-loss drugs and could provide a suggestion to anyone<a href="https://www.benzinga.com/24/12/42291702/obesity-drug-wars-heat-up-amgen-challenges-eli-lilly-novos-dominance"> trying to decide</a> between Eli Lilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Mounjaro and Novo Nordisk's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic for weight-loss treatment.
The <a href="https://x.com/elonmusk/status/1872086971557761348">post </a>from Musk called himself "Ozempic Santa." Despite the post labeled with Ozempic, Musk admitted in the comments that it is actually Mounjaro that he has taken for weight-loss support.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Ozempic Santa <a href="https://t.co/7YECSNpWoz">pic.twitter.com/7YECSNpWoz</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1872086971557761348?ref_src=twsrc%5Etfw">December 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
"Technically, Mounjaro, but that doesn't have the same ring to it," Musk tweeted.
Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also increasing in popularity as weight-loss options for people around the world.
When it comes to the two weight-loss drug options, Musk shared his personal takes on both.
"High doses of Ozempic made me fart &amp; burp like Barney from The Simpson's. Mounjaro seems to have fewer side effects and be more effective," Musk said.
With the Christmas posts, Musk has now shared publicly that he has tried Mounjaro, Ozempic and Wegovy, another treatment from Novo Nordisk.
You may not be a billionaire like Elon Musk, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/general/social-media/24/12/42490690/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: Musk's Christmas post, continues his public support for weight-loss drugs.
After &#8220;South Park&#8221; aired a special mocking weight-loss drugs as a luxury for the wealthy, the billionaire<a href="https://www.benzinga.com/news/24/05/39019043/elon-musk-says-ozempic-will-become-very-cheap-after-new-comedy-special-paints-it-as-weight-loss-drug"> predicted these medications</a> would become more affordable over time.
In May, responding to a post about childhood obesity, <a href="https://www.benzinga.com/news/24/05/38634420/ozempic-ftw-elon-musk-touts-novo-nordisks-blockbuster-drug-as-solution-to-childhood-obesity-problem">Musk signaled support</a> for weight-loss medications by posting &#8220;Ozempic ftw&#8221; (for the win), suggesting these drugs could be a future tool against the epidemic.
The billionaire's future battle <a href="https://www.benzinga.com/general/health-care/24/12/42607280/elon-musk-vs-rfk-jr-obesity-crisis-debate-sparks-struggle-for-trumps-influence">could be convincing</a> Robert F. Kennedy Jr. and Donald Trump that Americans need more access to affordable weight-loss drugs like Mounjaro. Musk is arguing for more access while Kennedy, who Trump said will be nominated to lead the Health and Human Services, supports healthier eating to fight obesity.
NVO, LLY Price Action: Novo Nordisk stock trades at $87.56 at the time of writing. The stock is down 14% year-to-date in 2024 and up 200.6% over the last five years.
Eli Lilly stock trades at $795.87 at the time of writing. The stock is up 34% year-to-date in 2024 and up 504.7% over the last five years.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41036415/eli-lilly-stock-soars-in-2024-on-weight-loss-drug-success-now-the-company-wants-medical-records-o">Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments</a></li>
</ul>
Photo: Shutterstock

Trading Ideas

Musk Tests Mounjaro, Ozempic, Wegovy: Which Weight-Loss Drug Won Him Over?

Tech stocks began Christmas week with positive momentum, as the Nasdaq 100 rose 0.4% on Monday, building on a 0.7% gain from Friday. The index has now recovered nearly half of the losses sustained following the <a href="https://www.benzinga.com/topic/federal-reserve">Federal Reserve's recent policy meeting.</a>
Semiconductors stood out as the top-performing sector:
<ul>
<li>iShares Semiconductor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NYSE">SOXX</a>) jumping 2.3%.</li>
<li>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), up 4.7%</li>
<li>Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), which surged 4.9%.</li>
</ul>
Meanwhile, other major indices showed minimal movement in what appeared to be a session marked by low trading volumes.
Consumer staples emerged as the weakest sector, with notable declines in major retailers. Dollar General Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) dropped 3.3%, while Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) shed 2.8%. 
In economic news, U.S. consumer confidence fell sharply in December, with the index dropping 8.1 points to 104.7 amid worsening expectations in future economic conditions.
The U.S. dollar index edged higher, mirroring a further surge in Treasury yields. The yield on the 10-year Treasury note rose 4 basis points to 4.57%, approaching its highest closing level since late May.
In commodities, gold slipped 0.4%, set to break a two-session winning streak, while oil prices declined 1%.
In the cryptocurrency market, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell 1.7% to around $93,000, eyeing its fifth loss in the past six sessions.
Shares of MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) tumbled over 4% in their first trading session after the company's inclusion in the Nasdaq 100 index.
<h3 class="wp-block-heading">Monday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,373.71</td>
<td>0.4%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,932.42</td>
<td>0.0%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,232.71</td>
<td>-0.4%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,620.75</td>
<td>-0.5%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:30 p.m. ET </figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) edged 0.1% higher to $592.12.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;eased 0.4% to $427.22.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.4% to $520.67.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.4% to $221.06.</li>
<li>The&nbsp;Technology Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up by 0.5%; the&nbsp;Consumer Staples Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) lagged, down 2%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
<ul>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) rose 3% following a 17.8% drop on Friday. The U.S. Food and Drug Administration announced on Monday that it has approved Hikma Pharmaceuticals&#8217; generic version of Novo Nordisk&#8217;s Victoza for treating type 2 diabetes.</li>
<li>New Fortress Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) rallied 18%, after Stifel raised the stock price target from $16 to $18. </li>
<li>Carnival Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) fell over 4% following a 6.4% post-earning rally Friday. </li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42653753/history-may-hint-at-sp-500-struggles-in-2025-yet-there-is-also-hope-heres-why">History Suggests S&amp;P 500 Could Struggle In 2025, But There&#8217;s Reason For Optimism</a></li>
</ul>
Image: Shutterstock

Tech

$BTC

AVGO

SPDR Dow Jones Industrial Average ETF Trust

MSTR

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

XLRE

Tech Stocks Eye Christmas Gains, Microstrategy Tumbles As Bitcoin Dips To $93,000: What's Driving Markets Monday?

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) shares rose by nearly 5% in pre-market trading on Monday, as per <a href="https://pro.benzinga.com/">Benzinga Pro</a>. This follows a significant 17.8% drop on Friday, which was triggered by disappointing results from a Phase III trial of its weight-loss drug, CagriSema.
What Happened:&nbsp;The Danish pharmaceutical company experienced a €90 billion reduction in market value after the REDEFINE 1 study revealed that CagriSema&#8217;s weight-loss benefits were comparable to&nbsp;Eli Lilly&#8217;s&nbsp;Zepbound, but with poorer tolerability. The trial indicated that patients using CagriSema lost an average of 22.7% of their weight over 68 weeks, while those on a placebo lost 2.3%.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/24/12/42572520/2025-housing-market-looks-like-a-year-of-struggle-for-states-like-builders-now-hold-record-inventory?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;2025 Housing Market Looks Like A Year Of Struggle For States Like …&#8217; – Builders Now Hold Record Inventory</a>
Talking<a href="https://www.marketwatch.com/story/novo-nordisks-27-drop-was-market-overreaction-analysts-say-fabe03c6?ref=biztoc.com"> to</a> Markets Watch, analysts at Intron Health, led by Naresh Chouhan, suggested that Friday&#8217;s market reaction was excessively severe. They highlighted&nbsp;that ongoing trials of CagriSema&nbsp;and Semaglutide might offer investors positive insights soon. This perspective has contributed to the rebound in&nbsp;Novo Nordisk&#8217;s&nbsp;stock price, as investors reassess the potential of the company&#8217;s weight-loss treatments.
Why It Matters: The recent fluctuations in&nbsp;Novo Nordisk&#8217;s&nbsp;stock have been closely watched by analysts and investors alike. According to a&nbsp;recent analysis, analysts&#8217; ratings for Novo Nordisk have varied from <a href="https://www.benzinga.com/insights/analyst-ratings/24/12/42645373/what-analysts-are-saying-about-novo-nordisk-stock">bullish to bearish </a>over the last quarter. The 12-month price targets set by analysts reveal an average target of $145.25, with a high estimate of $160.00 and a low of $105.00. This represents an 8.65% drop in the current average compared to the previous average price target of $159.00.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42635671/analyst-bullish-on-shiba-inu-sees-235-surge-despite-recent-fall?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Analyst Bullish on Shiba Inu, Sees 235% Surge Despite Recent Fall</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Equities

Pre-Market Outlook

Markets

Novo Nordisk Rises 5% In Premarket As Analyst Dismisses Friday's 17% Plunge As Market Overreaction

Analysts' ratings for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $145.25, a high estimate of $160.00, and a low estimate of $105.00. A 8.65% drop is evident in the current average compared to the previous average price target of $159.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1734958894_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Novo Nordisk. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$156.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Novo Nordisk. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Novo Nordisk compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Novo Nordisk's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NVO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Novo Nordisk analyst ratings.</a>
<h2>Get to Know Novo Nordisk Better</h2>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
<h3>Novo Nordisk: Financial Performance Dissected</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Novo Nordisk displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 21.42%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Novo Nordisk's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 38.28% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Novo Nordisk's ROE excels beyond industry benchmarks, reaching 23.43%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Novo Nordisk's ROA stands out, surpassing industry averages. With an impressive ROA of 7.12%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.47.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What Analysts Are Saying About Novo Nordisk Stock

BMO Capital analyst Evan David Seigerman maintains Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) with a Outperform and lowers the price target from $156 to $105.

Price Target

BMO Capital Maintains Outperform on Novo Nordisk, Lowers Price Target to $105

These eleven large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) shares dipped 20.52% after the company released headline results from the REDEFINE 1 Phase 3 <a href="https://www.benzinga.com//node/42613036" target="_blank" rel="noreferrer noopener">trial in the global REDEFINE program</a>.</li>
<li>Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) stock declined 14.33% after the company announced results from its <a href="https://www.benzinga.com//node/42599745" target="_blank" rel="noreferrer noopener">Phase 2 study of Suzetrigine</a>.</li>
<li>XPO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) shares were down 13.47%.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares fell 13.33% last week as the company is <a href="https://www.benzinga.com//node/42520765" target="_blank" rel="noreferrer noopener">set to be removed</a> from the Nasdaq 100 Index.</li>
<li>Nu Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) stock plummeted 13.07%. A new government fiscal spending package and last week&#8217;s central bank rate hike could erode global investor confidence and raise concerns over the nation&#8217;s deficit.</li>
<li>Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) stock was down 13.01%, likely due to continued weakness stemming from its <a href="https://www.benzinga.com//node/42538739" target="_blank" rel="noreferrer noopener">ongoing legal dispute</a> with Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>).</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) shares decreased 12.08% after the company reported mixed earnings results and issued weak guidance for the current quarter. <a href="https://www.benzinga.com//node/42594359" target="_blank" rel="noreferrer noopener">Multiple analysts also lowered price forecasts</a>.</li>
<li>Paycom Software, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) stock lost 11.63% last week, a result of the Fed rate decision that caused a selloff in software stocks.</li>
<li>Cintas Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) stock declined 11.50% after the company reported <a href="https://www.benzinga.com//node/42588404" target="_blank" rel="noreferrer noopener">second-quarter financial results</a>. Several analysts lowered <a href="https://www.benzinga.com/quote/ctas/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Warner Bros. Discovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) <a href="https://www.benzinga.com//node/42603589" target="_blank" rel="noreferrer noopener">declined 11.43%</a>.</li>
<li>monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) stock dived 11.20% after Citigroup cut its price forecast <a href="https://www.benzinga.com/quote/mndy/analyst-ratings" target="_blank" rel="noreferrer noopener">on the stock from $338 to $302</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/12/42638256/teva-pharmaceutical-li-auto-and-darden-restaurants-are-among-top-large-cap-gainers-last-week-december-16-20-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

CTAS

CVNA

MNDY

PAYC

QCOM

SMCI

VRTX

Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio?

On Friday, the U.S. Food and Drug Administration approved Eli Lilly and Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) weight loss drug Zepbound for treating sleep apnea
What Happened: The FDA&#8217;s decision makes Zepbound the first approved drug treatment for patients with obesity and moderate-to-severe obstructive sleep apnea, or OSA.
&#8220;Too often, OSA is brushed off as &#8216;just snoring,'&#8221; said Julie Flygare, CEO of Project Sleep, in Eli Lilly&#8217;s press release. The condition affects an estimated 80 million Americans, with 20 million experiencing moderate-to-severe forms.
See Also: <a href="https://www.benzinga.com/24/12/42291702/obesity-drug-wars-heat-up-amgen-challenges-eli-lilly-novos-dominance">Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo&#8217;s Dominance</a>
In a separate release, the FDA underscored that Zepbound should be used in conjunction with a reduced-calorie diet and increased physical activity for optimal results.
The approval could significantly impact insurance coverage for Zepbound, potentially including Medicare, which currently restricts coverage for obesity drugs unless approved for additional health benefits, <a href="https://www.cnbc.com/2024/12/20/fda-approves-eli-lillys-weight-loss-drug-zepbound-for-sleep-apnea.html">noted</a> CNBC.
This development also gives Eli Lilly an edge over competitor Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), whose Wegovy isn&#8217;t approved for sleep apnea treatment.
Why It Matters: Zepbound's effectiveness was demonstrated in clinical trials. Results showed that nearly half of patients treated with the highest dose experienced disease resolution, the report noted.
This was defined by a significant reduction in their apnea-hypopnea index (AHI), a key metric in diagnosing OSA.
The approval also comes as Eli Lilly continues to <a href="https://www.benzinga.com/24/12/42370795/investments-in-eli-lillys-production-capabilities-reaches-23-billion-with-additional-3-billion-expansion-at-us-facility">expand its manufacturing capabilities</a>, including a $3 billion investment in Kenosha County, Wisconsin in December, to meet the growing demand for its diabetes and obesity medicines.
In October, Eli Lilly reported <a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua">third-quarter revenue</a> of $11.44 billion, a 20% increase year-over-year, but missed expectations of $12.10 billion. Zepbound generated $1.26 billion.
Price Action: As per <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, LLY shares increased by 1.35% to $767.76 on Friday. So far this year, LLY has risen by 29.65%.
The latest ratings from B of A Securities, Wolfe Research, and Deutsche Bank set an average price target of $1,004, indicating a potential upside of 30.77%.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/LLY/analyst-ratings"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/21033911/Screenshot-2024-12-21-at-2.09.01%E2%80%AFPM-1024x374.png" alt="" class="wp-image-702686" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41318886/eli-lillys-alzheimers-drug-raises-hopes-but-faces-regulatory-hurdles-in-europe">Eli Lilly&#8217;s Alzheimer&#8217;s Drug Raises Hopes but Faces Regulatory Hurdles in Europe</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug

Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has outperformed the market over the past 5 years by 11.03% on an annualized basis producing an average annual return of 24.01%. Currently, Novo Nordisk has a market capitalization of $377.67 billion. 
Buying $100 In NVO: If an investor had bought $100 of NVO stock 5 years ago, it would be worth $294.83 today based on a price of $85.03 for NVO at the time of writing.
<h3>Novo Nordisk's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734732019_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

<h3>Gainers</h3>
<ul>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares rose 114.6% to $1.03 during Friday's pre-market session. The company's market cap stands at $3.8 million. </li>
<li>Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares increased by 67.34% to $5.79. The market value of their outstanding shares is at $744.9 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares moved upwards by 62.19% to $3.99. The company's market cap stands at $3.3 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares increased by 37.77% to $0.6. The company's market cap stands at $8.3 million. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) shares rose 29.25% to $30.75. The market value of their outstanding shares is at $162.2 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares rose 16.55% to $3.45. The market value of their outstanding shares is at $3.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) stock declined by 53.1% to $0.16 during Friday's pre-market session. The market value of their outstanding shares is at $1.0 million. </li>
<li>Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) stock decreased by 38.5% to $1.23. The market value of their outstanding shares is at $77.1 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) shares declined by 32.43% to $0.44. The market value of their outstanding shares is at $2.2 million. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) stock decreased by 21.86% to $0.93. The company's market cap stands at $44.9 million. </li>
<li>Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) shares declined by 20.14% to $82.61. The company's market cap stands at $366.9 billion. </li>
<li>Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) shares decreased by 17.71% to $2.51. The company's market cap stands at $10.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEMD

BCAB

GALT

HSDT

ISPC

MNPR

QNRX

SSKN

12 Health Care Stocks Moving In Friday's Pre-Market Session

Macro Economic Events

Macro Notification

Market Summary

Economics

DXCM

TNDM

Benzinga Market Summary: S&P Rises On PCE Data, Novo Nordisk Falls On Weight Loss Data, Diabetes Stocks Rise

U.S. stocks traded higher toward the end of trading, with the Dow Jones index jumping more than 600 points on Friday.
The Dow traded up 1.55% to 43,000.53 while the NASDAQ rose 1.65% to 19,693.06. The S&amp;P 500 also rose, gaining, 1.53% to 5,956.61.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a>
Leading and Lagging Sectors Real estate shares jumped by 2.4% on Friday.
In trading on Friday, consumer staples shares rose by just 0.4%.
Top Headline
The total number of active U.S. oil rigs climbed by 1 to 483 rigs this week, Baker Hughes Inc reported.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares shot up 40% to $4.8500 after the company announced FDA approval for SYMVESS for treating extremity vascular injuries. HC Wainwright &amp; Co. raised its price target on the stock from $12 to $15.</li>
<li>Shares of Personalis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>)got a boost, surging 25% to $6.55 after the company and Moderna recently announced a multi-year extension to continue utilizing the Personalis ImmunoID NeXT platform and technology for V940/mRNA-4157. The company also announced an investment from Merck.</li>
<li>Taoping Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>) shares were also up, gaining 37% to $0.4349 after the company announced it received an additional 180 calendar days for compliance with the Nasdaq minimum bid price requirement.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares dropped 74% to $0.4276 as the company reported the pricing of $20.0 million follow on offering.</li>
<li>Shares of Galectin Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) were down 54% to $0.9297 after the company announced top-line results of its NAVIGATE clinical trial and confirmed belapectin did not achieve statistical significance.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) was down, falling 17% to $85.72. The company announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE program.</li>
</ul>
Commodities In commodity news, oil traded up 0.1% to $69.43 while gold traded up 1.5% at $2,648.30.
Silver traded up 2.7% to $30.210 on Friday, while copper rose 0.8% to $4.1075.
Euro zone
European shares were lower today. The eurozone's STOXX 600 dipped 0.88%, Germany's DAX fell 0.43% and France's CAC 40 declined 0.27%. Spain's IBEX 35 Index rose 0.24%, while London's FTSE 100 fell 0.26%.
Consumer confidence in the Eurozone declined by 0.8 points to a reading of -14.5 in December.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 falling 0.29%, Hong Kong's Hang Seng Index falling 0.16%, China's Shanghai Composite Index declining 0.06% and India's BSE Sensex falling 1.49%.
Economics
<ul>
<li>The University of Michigan consumer sentiment rose to 74 in December, recording the highest level since April, and versus a reading of 71.8 in November.</li>
<li>U.S. personal income increased by 0.3% month-over-month in November compared to a revised 0.7% gain in October.</li>
<li>Personal spending increased by 0.4% to an annualized rate of $20.2 trillion in November.</li>
<li>The U.S. personal consumption expenditures price index rose 0.1% month-over-month in November down from 0.2% in each of the prior two months and compared to market estimates of 0.2%.</li>
<li>The total number of active U.S. oil rigs climbed by 1 to 483 rigs this week, Baker Hughes Inc reported.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42616304/top-3-risk-off-stocks-that-may-collapse-this-month">Top 3 Risk Off Stocks That May Collapse This Month</a></li>
</ul>

Earnings

Eurozone

Commodities

Intraday Update

PSNL

TAOP

Dow Surges Over 600 Points, Gold Jumps 1.5%

Risk sentiment returned to Wall Street on Friday, revitalized by softer-than-expected November inflation data leading to a strong market rebound following the selloff triggered by the <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42615908/feds-preferred-inflation-gauge-falls-more-than-expected-markets-breathe-sigh-of-relief">Federal Reserve&#8217;s recent meeting.</a>
The Personal Consumption Expenditure price index rose 2.4% year-over-year in November, falling short of the 2.5% increase forecasted. The core PCE, a key gauge closely watched by the Fed, also missed expectations, rising 2.8% compared to the anticipated 2.9%.
By midday Friday, all major indices were in rally mode, with broad-based gains across sectors. In the S&amp;P 500, 480 companies traded higher, and every sector advanced as investors welcomed the reprieve in inflationary pressures.
The real estate sector led the charge, rebounding sharply after being hit hardest in the aftermath of the Fed meeting. Small-cap stocks in the Russell 2000 also posted robust gains, powered by a strong recovery in regional banks.
The travel industry soared, driven by upbeat earnings and optimistic guidance from Carnival Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>), which fueled enthusiasm across the sector. The cruise line rose by 6%, eyeing the highest close since October 2021. 
In the bond market, yields dropped by approximately 5 basis points across the curve, boosting Treasury prices. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) gained nearly 1%, recovering some ground after a 3% slide over the previous two sessions. The dollar softened, declining 0.6%, while gold gained over 1%. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) attracted dip buyers after plunging to $92,118. Although the cryptocurrency pared its daily losses, it remains on track for its worst weekly performance in four months.
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,853.53</td>
<td>1.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,934.51</td>
<td>1.1%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,246.04</td>
<td>1.1%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,339.90</td>
<td>1.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:30 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1.1% to $592.31.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 1.2% to $429.61.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) edged 1.4% higher to $521.53.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) soared 1.2% to $222.59.</li>
<li>The&nbsp;Real Estate Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) outperformed, up by 2.3%; the&nbsp;Consumer Staples Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) lagged, up 0.6%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<ul>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) plummeted 17%, marking its worst single-day drop since April 2002. after disappointing weight-loss trial data for<a href="https://www.benzinga.com/government/regulations/24/12/42623343/exclusive-weight-loss-market-experts-scoop-up-novo-nordisk-stock-after-worst-drop-since-2002-following-drug-trial-miss"> its obesity drug, CagriSema.</a></li>
<li>Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) rallied over 8% as analysts at OTR Research raised the stock rating from Negative to Mixed.</li>
<li>Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) also rallied over 6% in reaction to Carnival Cruise&#8217;s upbeat results. Other travel-related companies seeing strong gains Friday included Airbnb Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>), up 3.9%, Hyatt Hotels Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>), up 3.4%, and Royal Caribbean Cruise Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>), up 3.6%.</li>
<li>Nike Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) fell 1.2% in reaction to its latest quarterly results and FedEx Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) inched 0.6% higher. </li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42623343/exclusive-weight-loss-market-experts-scoop-up-novo-nordisk-stock-after-worst-drop-since-2002-following-drug-trial-miss">EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Bonds

Broad U.S. Equity ETFs

Travel

Treasuries

Econ #s

ETFs

ABNB

ENPH

NCLH

iShares Trust Barclays 20+ Year Treasury Bond Fund

Wall Street Rallies On Soft Inflation Data, Bonds Rebound, Travel Stocks Surge: What's Driving Markets Friday?

On Friday,&nbsp;Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) released headline results from the REDEFINE 1 Phase 3 trial in the&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42613036/novo-nordisks-hybrid-weight-loss-drug-falls-short-on-expectations-stock-plunges" rel="noreferrer noopener">global REDEFINE program</a>.
When evaluating the effects of treatment if all people adhered to treatment, people treated with CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with placebo alone.
In November, Novo Nordisk said its hybrid drug, CagriSema, aims to reduce weight by 25% without&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41706292/as-race-to-best-miracle-obesity-drug-heats-up-ozempic-maker-novo-nordisk-tests-new-hybrid-drug-th" rel="noreferrer noopener">added side effects</a>.
William Blair points out that Novo Nordisk didn&#8217;t provide detailed tolerability data in its press release, making it hard to compare their treatment with Eli Lilly&#8217;s Zepbound directly. However, only 57% of patients could increase their dose to the highest level with CagriSema, compared to 83% with cagrilintide and 70% with Wegovy, suggesting that CagriSema may have a tougher tolerability profile.
The analyst writes the tolerability issue is a key reason why investors are concerned about the REDEFINE 1 trial. The analyst <a href="https://www.benzinga.com/quote/amgn/analyst-ratings" target="_blank" rel="noreferrer noopener">rates the shares Outperform</a>.
The results from CagriSema are also beneficial for Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), which recently showed that its GLP-1R agonist/GIPR antagonist, MariTide, leads to effective <a target="_blank" href="https://www.benzinga.com/24/11/42189129/amgen-reveals-data-from-closely-watched-monthly-obesity-drug-with-weight-loss-of-up-to-20-at-one-year-and-no-plateau" rel="noreferrer noopener">weight loss in Phase 2 trials.</a>
MariTide&#8217;s weight loss of about 20% after 52 weeks (or 18% at the 420 mg dose) is similar to or slightly below the weight loss seen with other GLP-1 therapies, such as CagriSema and Zepbound.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41950871/amgen-defends-its-investigational-monthly-weight-loss-injection-after-analyst-cites-maritides-impact-on-bone-density" rel="noreferrer noopener">Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide&#8217;s Impact on Bone Density</a>
The analyst writes that MariTide&#8217;s advantage could lie in its less frequent monthly dosing, which may stand out in the obesity market.
Additionally, the way MariTide is dosed appears to reduce gastrointestinal side effects with the first dose, suggesting it may have a more tolerable long-term profile and improve patient adherence.
Price Action: AMGN stock is up 1.58% at $265.33 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42621868/nvidia-secures-eu-approval-for-runai-deal-us-probes-china-export-breach" target="_blank" rel="noreferrer noopener">Nvidia Secures EU Approval For Run:ai Deal, US Probes China Export Breach</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

AMGN

What's Going On With Amgen Stock On Friday?

U.S. stocks traded higher midway through trading, with the Nasdaq Composite jumping more than 300 points on Friday.
The Dow traded up 1.82% to 43,111.11 while the NASDAQ rose 1.77% to 19,714.27. The S&amp;P 500 also rose, gaining, 1.76% to 5,970.36.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a>
Leading and Lagging Sectors Real estate shares jumped by 2.6% on Friday.
In trading on Friday, consumer staples shares rose by just 0.6%.
Top Headline
The U.S. personal consumption expenditures price index rose 0.1% month-over-month in November down from 0.2% in each of the prior two months and compared to market estimates of 0.2%.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares shot up 40% to $4.8500 after the company announced FDA approval for SYMVESS for treating extremity vascular injuries. HC Wainwright &amp; Co. raised its price target on the stock from $12 to $15.</li>
<li>Shares of Personalis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>)got a boost, surging 25% to $6.55 after the company and Moderna recently announced a multi-year extension to continue utilizing the Personalis ImmunoID NeXT platform and technology for V940/mRNA-4157. The company also announced an investment from Merck.</li>
<li>Taoping Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>) shares were also up, gaining 31% to $0.4153 after the company announced it received an additional 180 calendar days for compliance with the Nasdaq minimum bid price requirement.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares dropped 74% to $0.4173 as the company reported the pricing of $20.0 million follow on offering.</li>
<li>Shares of Galectin Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) were down 53% to $0.9499 after the company announced top-line results of its NAVIGATE clinical trial and confirmed belapectin did not achieve statistical significance.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) was down, falling 17% to $86.01. The company announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE program.</li>
</ul>
Commodities In commodity news, oil traded down 0.6% to $68.97 while gold traded up 1.5% at $2,645.80.
Silver traded up 1.6% to $29.890 on Friday, while copper rose 0.4% to $4.0925.
Euro zone
European shares were lower today. The eurozone's STOXX 600 dipped 0.99%, Germany's DAX fell 0.59% and France's CAC 40 declined 0.37%. Spain's IBEX 35 Index fell 0.10%, while London's FTSE 100 fell 0.25%.
Consumer confidence in the Eurozone declined by 0.8 points to a reading of -14.5 in December.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 falling 0.29%, Hong Kong's Hang Seng Index falling 0.16%, China's Shanghai Composite Index declining 0.06% and India's BSE Sensex falling 1.49%.
Economics
<ul>
<li>The University of Michigan consumer sentiment rose to 74 in December, recording the highest level since April, and versus a reading of 71.8 in November.</li>
<li>U.S. personal income increased by 0.3% month-over-month in November compared to a revised 0.7% gain in October.</li>
<li>Personal spending increased by 0.4% to an annualized rate of $20.2 trillion in November.</li>
<li>The U.S. personal consumption expenditures price index rose 0.1% month-over-month in November down from 0.2% in each of the prior two months and compared to market estimates of 0.2%.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42616304/top-3-risk-off-stocks-that-may-collapse-this-month">Top 3 Risk Off Stocks That May Collapse This Month</a></li>
</ul>

Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) is seeing its stock spiral downwards, with shares plummeting 20% early Friday following the <a href="https://www.benzinga.com/government/regulations/24/12/42623343/exclusive-weight-loss-market-experts-scoop-up-novo-nordisk-stock-after-worst-drop-since-2002-following-drug-trial-miss">release of Phase 3 trial data.</a>
While the headlines point to a new trial result that failed to meet expectations, the technical analysis reveals a deeper, more concerning picture of the stock&#8217;s momentum.
<a href="https://www.benzinga.com/24/12/42613036/novo-nordisks-hybrid-weight-loss-drug-falls-short-on-expectations-stock-plunges">Read News Details: Novo Nordisk&#8217;s Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges</a>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="493" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095235/Screenshot-2024-12-20-at-8.18.29-PM.png" alt="" class="wp-image-701951" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095235/Screenshot-2024-12-20-at-8.18.29-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095235/Screenshot-2024-12-20-at-8.18.29-PM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122024&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
<h2 class="wp-block-heading">NVO Stock Has Bearish Signals Across The Board</h2>
NVO's charts are filled with clear signs of weakness, and the technicals are currently dominated by bearish trends. 
Here&#8217;s a breakdown of what the indicators are signaling:
<ul>
<li>Exponential Moving Averages (EMAs): NVO stock is trading below its five, 20, and 50-day EMAs, marking a distinct downtrend. A sustained move below these averages generally indicates a lack of bullish momentum and suggests further downside potential in the near term.</li>
<li>Simple Moving Averages (SMAs): Novo Nordisk's stock price of $82.70 is significantly below its eight-day simple moving average (SMA) of $104.43, 20-day SMA of $106.54 and 50-day SMA of $109.23. With all these moving averages acting as resistance levels, the bearish sentiment remains entrenched. Furthermore, the price is well below the 200-day SMA of $126.23, reinforcing the ongoing downtrend.</li>
<li>MACD (Moving Average Convergence Divergence): The MACD reading of a negative 2.68 is a clear sign of negative momentum. A negative MACD indicates that the short-term moving averages are below the long-term averages, further validating the lack of bullish pressure and signaling that the stock could remain under selling pressure.</li>
<li>RSI (Relative Strength Index): NVO's RSI is currently at 18.58, a deeply oversold level. While this could suggest that the stock is due for a short-term bounce, it also points to how overextended NVO stock has become to the downside. Historically, an RSI this low can signal that a reversal is due, but with the broader trend still bearish, any bounce might be short-lived and met with renewed selling.</li>
</ul>
For now, NVO stock is in a strong technical downtrend, with little immediate indication that it will break free from the selling pressure.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42616290/us-steel-issues-weak-q4-outlook-joins-novo-nordisk-and-other-big-stocks-moving-lower-in-fridays-pre-market-session">US Steel Issues Weak Q4 Outlook, Joins Novo Nordisk And Other Big Stocks Moving Lower In Friday&#8217;s Pre-Market Session</a></li>
</ul>
Photo: Shutterstock

Technicals

Novo Nordisk Stock Plummets: Bearish Signals Dominate After Drug Trial Miss

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) saw its stock crater nearly 20% on Friday, eyeing its worst single-day drop since April 2002, after releasing underwhelming weight-loss trial results for its much-hyped <a href="https://www.benzinga.com/24/12/42613036/novo-nordisks-hybrid-weight-loss-drug-falls-short-on-expectations-stock-plunges">obesity drug, CagriSema. </a>
To put the move in perspective, the only steeper plunge in the Danish pharma giant's history was a 26.2% collapse during the infamous Black Monday crash of October 1987.
Once the poster child of the obesity drug boom, Novo failed to meet the market's sky-high expectations, sparking a $20 billion wipe out in market value.
Here's what happened—and why some analysts believe Wall Street might have overreacted.
<h3 class="wp-block-heading">Trial Results Fall Short of High Expectations</h3>
CagriSema, a combination of cagrilintide and semaglutide, is part of Novo Nordisk's REDEFINE clinical program, designed to compete in the lucrative obesity drug market. 
The REDEFINE 1 Phase 3 trial, which involved 3,417 participants with obesity or overweight conditions, demonstrated a 22.7% weight loss after 68 weeks for patients taking CagriSema. 
While impressive compared to the 2.3% weight loss with placebo, the result was slightly below Novo's previously teased goal of a 25% reduction.
By comparison:
<ul>
<li>CagriSema: 22.7% weight loss</li>
<li>Semaglutide alone: 16.1% weight loss</li>
<li>Cagrilintide alone: 11.8% weight loss</li>
<li>Placebo: 2.3% weight loss</li>
</ul>
Additionally, 40.4% of patients taking CagriSema lost at least 25% of their body weight, compared to just 16.2% with semaglutide and a negligible 0.9% with placebo.
While the trial data were statistically significant, they fell shy of the hype surrounding Novo's claims that CagriSema could deliver 25% weight loss without added side effects.
<h3 class="wp-block-heading">Analysts Call The Selloff &#8216;Overdone&#8217;</h3>
Despite the sharp decline, several industry insiders believe the market overreacted. 
Maurits Pot, founder of Tema ETFs, which manages the GLP-1 Obesity &amp; Cardiometabolic ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRTS#NYSE">HRTS</a>), told Benzinga: "This is the latest major event in the obesity space in what has proven to be a very volatile second half of the year.&#8221;
Tema ETFs had already been underweight Novo, holding just a 3.99% stake prior to the REDEFINE 1 results. 
Pot has been for long championing the case that the weight-loss market is far from being dominated by a duopoly – Novo Nordisk and Ely Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
&#8220;This latest readout from Novo today underscores why only betting on NOVO and LLY in the GLP-1 is very risky and has not worked in the second half of 2024,&#8221; he stated.
Despite this, he described Novo Nordisk&#8217;s sharp selloff as an &#8220;overreaction&#8221; and told Benzinga that the HRTS fund is taking advantage of Friday&#8217;s dip to add more shares.
Goldman Sachs analyst James Quigley offered a similar perspective in a note released Friday.
"While these weight loss data are lower than hoped in the market, we still believe that the product [CagriSema] will be filed and approved by the FDA,&#8221; Quigley stated.
The expert sees Novo's market position moving &#8220;from one where they had a clearly inferior product in Wegovy to one that is on par with Zepbound in terms of weight loss.&#8221;
&#8220;We see the share price move as overdone and with CagriSema offering another high efficacy option, it could still protect part of the longer term obesity franchise,&#8221; he added. 
Goldman maintained a bullish stance on Novo Nordisk, setting a 12-month price target of $148 for the ADR—a potential 75% upside from Friday's market price.
NVO Price Action: Shares of Novo Nordisk were down 18.5% to $84.25 at the time of publication Friday.
Read now: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/12/42612794/djt-stock-plummets-over-5-following-trumps-stake-transfer-heres-more">DJT Stock Plummets Over 5% Following Trump&#8217;s Stake Transfer: Here&#8217;s More</a></li>
</ul>
Photo: Shutterstock

Regulations

Sector ETFs

Exclusives

HRTS

EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss

Benzinga Market Summary: Novo Nordisk Falls On Weight Loss Data, Shares Of Competitor Lilly Rise, S&P Continues Higher

CORRECTION: Amgen shares are trading higher. Weight-loss related stocks are up on Friday following weaker-than-expected data from competitor Novo Nordisk.

<ul>
<li>TSLA</li>
<li>NVDA</li>
<li>AMD</li>
<li>MSTR</li>
<li>NVO</li>
<li>QQQ</li>
<li>CORN</li>
<li>$BTC</li>
<li>RKLB</li>
<li>AAPL</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

AAPL

CORN

NVDA

RKLB

TSLA

Top 10 Trending Stocks On WallStreetBets As Of December 20, 2024 (Via Swaggy Stocks)

U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Friday.
Shares of United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) fell sharply in today's pre-market trading after the company issued fourth-quarter adjusted EPS guidance <a href="https://www.benzinga.com/news/guidance/24/12/42606023/us-steel-stock-stumbles-on-weak-q4-outlook">below analyst estimates</a>.
After the market close on Thursday, U.S. Steel said it expects to report a fourth-quarter adjusted loss of 25 cents to 29 cents per share. Fourth-quarter adjusted EBITDA is expected to come in around $150 million.
U.S. Steel shares dipped 6.5% to $29.65 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) fell 25.8% to $76.80 in pre-market trading. Novo Nordisk said CagriSema demonstrated weight loss in adults with obesity or overweight in the REDEFINE 1 trial.</li>
<li>Innovative Industrial Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) dipped 19.1% to $77.10 in pre-market trading  after the company reported a default by Pharmacann on its obligations to pay rent for six of its eleven leases in December.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares fell 18.1% to $13.72 in pre-market trading. Mesoblast shares jumped over 36% on Thursday after the company announced the FDA approved Ryoncilas the first mesenchymal stromal cell therapy in the United States.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) fell 11.1% to $13.46 in pre-market trading after declining 41% on Thursday.</li>
<li>Arqit Quantum Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQQ#NASDAQ">ARQQ</a>) declined 7.2% to $24.98 in pre-market trading.</li>
<li>Transportadora de Gas del Sur S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGS#NYSE">TGS</a>) fell 5.4% to $26.01 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42609619/sp-500-nasdaq-end-in-red-as-investor-sentiment-declines-micron-tumbles-after-sales-miss-greed-index-in-extreme-fear-zone">S&amp;P 500, Nasdaq End In Red As Investor Sentiment Declines, Micron Tumbles After Sales Miss: Greed Index In &#8216;Extreme Fear&#8217; Zone</a></li>
</ul>

ARQQ

IIPR

US Steel Issues Weak Q4 Outlook, Joins Novo Nordisk And Other Big Stocks Moving Lower In Friday's Pre-Market Session

BMO Capital lowered the firm's price target on Novo Nordisk (NVO) to $105 from $156 but keeps an Outperform rating on the shares. The company's ant...

Novo Nordisk price target lowered to $105 from $156 at BMO Capital

Unusual total active option classes on open include: Equinix (EQIX), Tilray (TLRY), BlackBerry (BB), Lumen Technologies (LUMN), Faraday Future Inte...

Unusually active option classes on open December 23rd

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

FDA approves first generic of Novo Nordisk's Victoza

Pfizer: Time And Patience Ran Out (Rating Downgrade)

Novo Nordisk: Aggressive Dip-Buying Opportunity Has Finally Arrived

Carillon ClariVest International Stock Fund Q3 2024 Commentary

Elon Musk says he prefers Lilly's Mounjaro over Novo's Ozempic

2025 Analyst Outlook: Edmund Ingham On Biotech Big And Small, And A Key Milestone

Elon Musk took to X on Wednesday to reveal his preference for Eli Lilly's ($LLY) weight-loss drug Mounjaro over Novo Nordisk's ($NVO) Ozempic. Both...

Elon Musk Prefers Eli Lilly's (LLY) Mounjaro over Novo Nordisk's Ozempic

ASML

BABA

ENVX

EQIX

FFIE

FUBO

GPCR

HXSCF

LUMN

LUNR

NONOF

ONCY

QABSY

QUBSF

RHHBY

RNLSY

RNSDF

SSNLF

TCOM

TERN

TEVA

TGOPF

TGOPY

TLRY

VKTX

Screenshot 2024-11-20 at 6.30.30 PM

BRTX

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Press Releases

Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033

RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Management

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

Opinion

Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition

Health and Wellness Industry Embraces Surge in Demand for Weight Loss Drugs

Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

BioRestorative Ends Q3 In 'Strong' Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Comments

Novo Nordisk

Noticias

Últimas noticias sobre Novo Nordisk (NYSE:NVO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL